دورية أكاديمية
أعرض في EDS

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.

التفاصيل البيبلوغرافية
العنوان: Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.
المؤلفون: Mahaling B; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Low SWY; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Ch S; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad 500078, India., Addi UR; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Ahmad B; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Connor TB; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Mohan RR; One-Health One-Medicine Ophthalmology and Vision Research Program, University of Missouri, Columbia, MO 65211, USA., Biswas S; Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad 500078, India., Chaurasia SS; Ocular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.; Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
المصدر: Pharmaceutics [Pharmaceutics] 2023 Jul 22; Vol. 15 (7). Date of Electronic Publication: 2023 Jul 22.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Retinal diseases are one of the leading causes of blindness globally. The mainstay treatments for these blinding diseases are laser photocoagulation, vitrectomy, and repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, these therapies are associated with ocular complications like inflammation, elevated intraocular pressure, retinal detachment, endophthalmitis, and vitreous hemorrhage. Recent advances in nanomedicine seek to curtail these limitations, overcoming ocular barriers by developing non-invasive or minimally invasive delivery modalities. These modalities include delivering therapeutics to specific cellular targets in the retina, providing sustained delivery of drugs to avoid repeated intravitreal injections, and acting as a scaffold for neural tissue regeneration. These next-generation nanomedicine approaches could potentially revolutionize the treatment landscape of retinal diseases. This review describes the availability and limitations of current treatment strategies and highlights insights into the advancement of future approaches using next-generation nanomedicines to manage retinal diseases.
References: Tissue Eng Part C Methods. 2020 Aug;26(8):433-446. (PMID: 32635833)
J Nanobiotechnology. 2019 May 13;17(1):64. (PMID: 31084611)
ACS Nano. 2012 Sep 25;6(9):7595-606. (PMID: 22876910)
Front Cell Neurosci. 2015 Dec 22;9:484. (PMID: 26733810)
Angiogenesis. 2007;10(2):103-17. (PMID: 17340211)
ScientificWorldJournal. 2013 Dec 14;2013:732340. (PMID: 24396306)
J Ophthalmic Vis Res. 2022 Jan 21;17(1):58-68. (PMID: 35194497)
Pharmaceutics. 2020 Jan 02;12(1):. (PMID: 31906576)
Pharmaceutics. 2021 Dec 28;14(1):. (PMID: 35056970)
Free Radic Biol Med. 2014 Oct;75:140-8. (PMID: 25066531)
Int J Mol Sci. 2017 Sep 20;18(9):. (PMID: 28930148)
Int J Mol Sci. 2014 Jan 22;15(1):1590-605. (PMID: 24451140)
Micromachines (Basel). 2020 May 28;11(6):. (PMID: 32481670)
J Ocul Pharmacol Ther. 2013 Mar;29(2):173-88. (PMID: 23286300)
Nano Today. 2015 Feb 1;10(1):93-117. (PMID: 25893004)
Small. 2018 Jan;14(2):. (PMID: 29154484)
Invest Ophthalmol Vis Sci. 2011 Sep 21;52(10):7289-97. (PMID: 21849425)
Nanoscale Adv. 2021 Aug 10;3(18):5240-5254. (PMID: 36132623)
J Control Release. 2013 Dec 28;172(3):625-33. (PMID: 24126220)
Curr Opin Pediatr. 2018 Dec;30(6):725-733. (PMID: 30234647)
Nanomedicine. 2011 Aug;7(4):505-13. (PMID: 21272669)
Polymers (Basel). 2021 Sep 28;13(19):. (PMID: 34641139)
J Ophthalmol. 2016;2016:2371021. (PMID: 27200182)
Gene Ther. 2005 Nov;12(21):1544-50. (PMID: 16034458)
J Biomater Sci Polym Ed. 2020 Jun;31(8):1071-1090. (PMID: 32149562)
Cell. 2019 Apr 4;177(2):243-255.e15. (PMID: 30827682)
Retina. 2007 Sep;27(7):816-24. (PMID: 17891003)
Biomaterials. 2019 Oct;217:119285. (PMID: 31299627)
Curr Drug Deliv. 2016;13(4):590-9. (PMID: 26279119)
Int J Mol Sci. 2019 Dec 23;21(1):. (PMID: 31877924)
J Control Release. 2023 Mar;355:358-370. (PMID: 36738972)
Nat Commun. 2019 Feb 18;10(1):804. (PMID: 30778060)
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1595-639. (PMID: 16198021)
Exp Eye Res. 2022 Feb;215:108906. (PMID: 34953864)
Acta Biomater. 2013 Dec;9(12):9414-22. (PMID: 23917149)
Cell Transplant. 2012;21(6):1137-48. (PMID: 22405427)
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1638-49. (PMID: 18840488)
J Drug Deliv. 2011;2011:863734. (PMID: 21490757)
Pharmaceutics. 2022 Sep 16;14(9):. (PMID: 36145708)
Int J Biol Macromol. 2023 Jan 1;224:810-830. (PMID: 36302483)
Clin Interv Aging. 2017 Aug 22;12:1313-1330. (PMID: 28860733)
Colloids Surf B Biointerfaces. 2009 Oct 1;73(1):51-7. (PMID: 19481908)
Exp Eye Res. 2019 Nov;188:107805. (PMID: 31526807)
Pharmaceutics. 2021 Jun 08;13(6):. (PMID: 34200993)
J Biosci. 2017 Jun;42(2):299-309. (PMID: 28569253)
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3562-9. (PMID: 12882808)
J Control Release. 2017 Feb 28;248:96-116. (PMID: 28087407)
Drug Deliv Transl Res. 2023 Jun;13(6):1675-1698. (PMID: 36630075)
AAPS PharmSciTech. 2023 Feb 14;24(2):66. (PMID: 36788150)
ACS Appl Mater Interfaces. 2016 Mar 23;8(11):6834-40. (PMID: 26926578)
Appl Sci (Basel). 2021 Mar;11(5):. (PMID: 35251703)
Prog Retin Eye Res. 2012 Jan;31(1):43-64. (PMID: 21967960)
Pharmaceutics. 2021 Sep 30;13(10):. (PMID: 34683883)
Biotechniques. 2007 Mar;42(3):285-6, 288. (PMID: 17390533)
Int J Pharm. 2010 Jan 29;385(1-2):157-62. (PMID: 19835940)
Biochem Biophys Res Commun. 1996 Feb 27;219(3):947-50. (PMID: 8645284)
J Control Release. 2017 Feb 10;247:153-166. (PMID: 28063892)
Int J Pharm. 2021 Sep 5;606:120900. (PMID: 34293472)
RSC Adv. 2021 Aug 31;11(46):29065-29072. (PMID: 35478587)
Bioprinting. 2018 Dec;11:. (PMID: 31903439)
Gels. 2023 Apr 02;9(4):. (PMID: 37102904)
ACS Appl Mater Interfaces. 2019 Jun 5;11(22):20341-20349. (PMID: 31082187)
ACS Omega. 2020 Apr 06;5(14):7928-7939. (PMID: 32309702)
Drug Deliv. 2019 Dec;26(1):989-1001. (PMID: 31571502)
Nat Med. 2020 Mar;26(3):354-359. (PMID: 32094925)
Int J Mol Sci. 2018 Jun 20;19(6):. (PMID: 29925789)
Pharmacol Res. 2016 Sep;111:713-720. (PMID: 27475885)
Biomaterials. 2011 Mar;32(7):1865-71. (PMID: 21145587)
Int J Nanomedicine. 2021 Jul 02;16:4481-4494. (PMID: 34239300)
ACS Nano. 2015 Feb 24;9(2):1749-58. (PMID: 25585134)
Biomaterials. 2013 Jan;34(4):875-87. (PMID: 23131535)
BioDrugs. 2010 Oct 1;24(5):331-43. (PMID: 20795754)
Pharmaceutics. 2017 Mar 27;9(2):. (PMID: 28346375)
J Nanobiotechnology. 2021 Dec 20;19(1):436. (PMID: 34930292)
J Control Release. 2012 Jun 10;160(2):225-31. (PMID: 22138070)
Biomaterials. 2016 Jun;90:40-9. (PMID: 26986855)
J Nanopart Res. 2011 Oct;13(10):5547-5555. (PMID: 22039334)
Int J Pharm. 2013 Aug 30;453(1):198-214. (PMID: 22944304)
J Control Release. 2019 Jun 10;303:91-100. (PMID: 30986436)
Int J Pharm. 2016 Mar 30;501(1-2):1-9. (PMID: 26821059)
JAMA. 2013 May 15;309(19):2005-15. (PMID: 23644932)
Int J Nanomedicine. 2018 Jul 27;13:4379-4389. (PMID: 30100721)
mSphere. 2019 May 15;4(3):. (PMID: 31092603)
Nanotechnology. 2009 Dec 16;20(50):505101. (PMID: 19923650)
Drug Discov Today. 2008 Feb;13(3-4):144-51. (PMID: 18275912)
Expert Opin Biol Ther. 2003 Feb;3(1):45-56. (PMID: 12718730)
Biomed Pharmacother. 2023 Jul;163:114717. (PMID: 37435722)
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4413-24. (PMID: 26193917)
Int J Nanomedicine. 2019 Apr 29;14:2973-2983. (PMID: 31118616)
J Control Release. 2017 Jan 10;245:157-169. (PMID: 27919626)
Molecules. 2020 Sep 01;25(17):. (PMID: 32882920)
ACS Appl Bio Mater. 2020 May 18;3(5):3078-3086. (PMID: 34327311)
PLoS One. 2013 Jun 14;8(6):e66434. (PMID: 23799103)
J Control Release. 2022 Jul;347:449-459. (PMID: 35537538)
Int J Nanomedicine. 2019 Feb 25;14:1489-1501. (PMID: 30880960)
Biomaterials. 2019 Mar;197:284-293. (PMID: 30677557)
Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3. (PMID: 18320201)
AAPS PharmSciTech. 2020 Jan 21;21(3):74. (PMID: 31965399)
Adv Drug Deliv Rev. 2020;157:96-117. (PMID: 32579890)
J Control Release. 2016 Oct 28;240:109-126. (PMID: 26571000)
Pharmaceutics. 2023 Mar 29;15(4):. (PMID: 37111581)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Jul-Aug;7(4):509-33. (PMID: 25581024)
J Pharm Sci. 2013 Aug;102(8):2707-17. (PMID: 23839931)
Biomacromolecules. 2013 Mar 11;14(3):841-53. (PMID: 23394107)
Mater Sci Eng C Mater Biol Appl. 2013 Oct;33(7):3697-703. (PMID: 23910266)
Early Hum Dev. 2008 Feb;84(2):95-9. (PMID: 18280405)
ACS Omega. 2019 Apr 11;4(4):6660-6668. (PMID: 31459791)
Ophthalmology. 1983 May;90(5):522-30. (PMID: 6192378)
Expert Opin Drug Deliv. 2012 May;9(5):497-508. (PMID: 22439808)
J Biomater Appl. 2021 Mar;35(8):1019-1033. (PMID: 33290123)
Ther Deliv. 2017 Nov;8(11):967-985. (PMID: 29061106)
Eur J Pharm Biopharm. 2016 Dec;109:214-223. (PMID: 27789355)
Vet Ophthalmol. 2014 May;17(3):162-9. (PMID: 23718145)
Biomaterials. 2016 Mar;83:219-32. (PMID: 26774567)
J Clin Med. 2021 Oct 12;10(20):. (PMID: 34682788)
Bioconjug Chem. 1995 Jan-Feb;6(1):7-20. (PMID: 7711106)
PLoS One. 2006 Dec 20;1:e38. (PMID: 17183666)
Int J Pharm. 2020 Mar 15;577:119084. (PMID: 31988033)
Biomacromolecules. 2014 Mar 10;15(3):968-77. (PMID: 24527876)
Int J Pharm. 2022 May 25;620:121725. (PMID: 35405282)
Nanomedicine. 2016 Oct;12(7):2149-2160. (PMID: 27288669)
Mol Pharm. 2017 Feb 6;14(2):423-430. (PMID: 27936751)
ACS Appl Mater Interfaces. 2017 Aug 9;9(31):25706-25716. (PMID: 28741924)
Drug Deliv Transl Res. 2020 Aug;10(4):919-944. (PMID: 32270439)
Front Neurol. 2012 May 11;3:75. (PMID: 22593752)
AAPS PharmSciTech. 2015 Jun;16(3):610-22. (PMID: 25425389)
mSphere. 2017 Nov 22;2(6):. (PMID: 29202038)
Biology (Basel). 2021 Dec 15;10(12):. (PMID: 34943243)
J Ocul Pharmacol Ther. 2011 Jun;27(3):219-24. (PMID: 21574814)
Int Ophthalmol Clin. 2019 Winter;59(1):221-240. (PMID: 30585928)
Nat Nanotechnol. 2006 Nov;1(2):142-50. (PMID: 18654167)
J Control Release. 2009 Jun 19;136(3):247-53. (PMID: 19272407)
PLoS One. 2011;6(12):e28560. (PMID: 22162776)
J Ocul Pharmacol Ther. 2002 Dec;18(6):507-14. (PMID: 12537677)
Drug Deliv. 2016 May;23(4):1075-91. (PMID: 25116511)
Ophthalmology. 2016 Jul;123(7):1553-62. (PMID: 27040150)
Curr Opin Ophthalmol. 2022 May 1;33(3):137-146. (PMID: 35266893)
J Nanobiotechnology. 2009 Oct 30;7:8. (PMID: 19878566)
J Funct Biomater. 2015 Apr 30;6(2):277-98. (PMID: 25941990)
Ophthalmic Surg Lasers Imaging Retina. 2021 Jan 1;52(1):29-36. (PMID: 33471912)
Turk J Pharm Sci. 2021 Oct 28;18(5):652-664. (PMID: 34708428)
Nanotoxicology. 2010 Jun;4(2):207-46. (PMID: 20795897)
J Control Release. 2009 May 21;136(1):2-13. (PMID: 19331856)
J Control Release. 2019 Mar 28;298:177-185. (PMID: 30776396)
Biomaterials. 2012 Jan;33(3):979-88. (PMID: 22048009)
Molecules. 2020 Aug 15;25(16):. (PMID: 32824172)
ACS Omega. 2021 Feb 22;6(9):6172-6184. (PMID: 33718708)
Res Pharm Sci. 2018 Aug;13(4):288-303. (PMID: 30065762)
Eur J Pharm Biopharm. 2020 May;150:131-142. (PMID: 32151727)
Int J Pharm. 2023 Jun 25;641:122987. (PMID: 37207860)
Lancet Glob Health. 2021 Feb;9(2):e144-e160. (PMID: 33275949)
ACS Omega. 2017 Dec 31;2(12):8959-8968. (PMID: 30023596)
J Control Release. 2010 Mar 3;142(2):267-76. (PMID: 19861141)
Nanoscale. 2018 Sep 13;10(35):16485-16498. (PMID: 29897081)
ACS Nano. 2013 Apr 23;7(4):3264-75. (PMID: 23464925)
Int J Hyperthermia. 2016 Sep;32(6):657-65. (PMID: 27380542)
Eye (Lond). 2013 Jul;27(7):787-94. (PMID: 23722722)
Pharmaceutics. 2023 Feb 11;15(2):. (PMID: 36839933)
Clin Ophthalmol. 2020 Jul 24;14:2109-2118. (PMID: 32801619)
Nanotoxicology. 2020 Jun;14(5):577-594. (PMID: 31928284)
Drug Deliv. 2020 Jan 1;27(1):556-564. (PMID: 32351142)
Eur J Pharm Biopharm. 2015 Jan;89:271-9. (PMID: 25513956)
Eur J Pharmacol. 2005 Mar 28;511(2-3):191-8. (PMID: 15792788)
Eur J Pharm Biopharm. 2023 Jun;187:175-183. (PMID: 37088247)
J Pharm Pharmacol. 1980 Jun;32(6):381-5. (PMID: 6106667)
J Control Release. 2004 Aug 27;98(3):407-13. (PMID: 15312996)
Arch Ophthalmol. 1994 Jan;112(1):117-22. (PMID: 8285878)
Adv Drug Deliv Rev. 2005 Dec 13;57(14):2010-32. (PMID: 16289435)
Int J Mol Sci. 2022 Feb 26;23(5):. (PMID: 35269741)
Ophthalmic Surg. 1988 Jul;19(7):482-4. (PMID: 3412760)
Drug Discov Today. 2019 Aug;24(8):1660-1668. (PMID: 30958994)
Int J Pharm. 2012 Oct 15;436(1-2):564-7. (PMID: 22828072)
معلومات مُعتمدة: R01EY029795 and R01EY030077 National Institute of Health
فهرسة مساهمة: Keywords: nanodelivery; nanodevices; nanomedicines; nanoparticles; nanostructured scaffolds; retina
تواريخ الأحداث: Date Created: 20230729 Latest Revision: 20230801
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10383092
DOI: 10.3390/pharmaceutics15072005
PMID: 37514191
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics15072005